Navigation Links
BioVex Closes Second Round of Series E Financing
Date:11/15/2007

Second and Final Close Completes $35 Million Financing

WOBURN, Mass., Nov. 15 /PRNewswire/ -- BioVex Inc, a clinical stage company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it had completed its Series E financing, concurrent with the completion of a venture debt transaction, raising a total of $35m of funds.

BioVex intends to use the capital to complete its preparations for, and to commence, a Phase III study with its lead product OncoVex GM-CSF for the treatment of melanoma as well as to complete studies in head and neck cancer and pancreatic cancer. The financing will also fund the Company's second program, ImmunoVEX HSV2, a vaccine for genital herpes, through to Phase II.

The Series E placement was led by Triathlon Medical Ventures who were joined by new investors New Science Ventures and Harris and Harris Group, Inc., as well as existing investors. The venture debt facility was provided by Oxford Finance Corporation and Silicon Valley Bank.

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX GM-CSF, is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX GM-CSF is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX GM-CSF has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX GM-CSF as stand alone therapy in patients with un-resectab
'/>"/>

SOURCE BioVex Inc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... New York, NY (PRWEB) June 17, 2013 ... to announce the launch of the Chief Medical Officer Summit ... CMO West will take place in San Francisco on ... , For the first time, West Coast Chief Medical ... idea from Dr. Elizabeth Stoner, Managing Director of MPM Capital. ...
(Date:6/17/2013)... 17, 2013 Z Trim Holdings, Inc. ... providing value-added ingredients to a variety of industries, ... new meat application at this year,s annual Institute ... Chicago , July 13-16. The Company will ... expensive/chemically-modified ingredients in meat products thereby helping manufacturers ...
(Date:6/17/2013)... June 17, 2013 ... announced the addition of the "North ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics- Forecasts ... ,      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:6/17/2013)... As interest increases in developing novel biomarker and ... need to keep up with the pace of new ... first in a series titled “Better Methods for Novel ... range of technologies, introduces a novel method for more ... than either ELISA or traditional LCMS can achieve. , ...
Breaking Biology Technology:Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3Quantitative Analysis of Biomarkers, New Life Science Webinar Hosted by Xtalks 2
... SANTA BARBARA, Calif., Nov. 15, 2011 FindTheBest,s Private ... parents seeking an accredited storage facility for their newborn,s cord ... and highly sensitive decision to make, particularly for families with ... parents a way to make the most informed decision when ...
... N.J., Nov. 15, 2011 Palatin Technologies, Inc. (NYSE ... targeted, receptor-specific peptide therapeutics for the treatment of diseases ... announced results for its first quarter ended September 30, ... or $(0.10) per basic and diluted share, for the ...
... 2011 A new retrospective subanalysis ... mesylate) capsules 150mg twice daily reduced the risk ... in patients with non-valvular atrial fibrillation (NVAF) irrespective ... with no significant interaction for major bleeding events.(1) ...
Cached Biology Technology:Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 2Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 3Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 4Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 5New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 2New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 3New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 4New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 5New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 6New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 7New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 8
(Date:6/17/2013)... 2013 An international team led by scientists at ... Institute and Albert Einstein College of Medicine of Yeshiva ... that attacks the tuberculosis (TB) bacterium in two different ... solve one of the major global health crises of ... strains," said Peter G. Schultz, the Scripps Family Chair ...
(Date:6/17/2013)... professors in Wayne State University,s Department of Physics ... Research Experience for Undergraduates (REU) program. This program ... cutting-edge research in astrophysics, and in particle and ... Ph.D., professor of physics in Wayne State,s College ... director of the grant, the student participants will ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Wayne State welcomes undergraduates from around the US for physics research experience 2'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... DNA mutations may shepherd in an era of small, ... of genes that harbor disease. , Joseph Wang, director ... Biodesign Institute at ASU, led a team effort that ... and nanotechnology to fashion nanocrystals that can act as ...
... the plagues of the Middle Ages have made around 10% ... time that these individuals carry a genetic mutation (known as ... the immune system but have been unable to account for ... low levels in areas bordering the Mediterranean. , They have ...
... team of researchers at Johns Hopkins Medical Institutions in ... (PET/CT) scans may help physicians identify new, unexpected malignant ... the May issue of the Society of Nuclear Medicine's ... additional lesions in patients known to have cancer," said ...
Cached Biology News:Bioelectronic ‘signatures?hold key to DNA mutations 2First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes 2PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment 2
...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: